NUTTAPOOM YOADJARUST: Open Payments
NPI 1447742028 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,724 in 182 payments from 21 companies in 2025. Trend: 2023 $4,269 · 2024 $3,885 · 2025 $4,724
Food & beverage: $4,625Education: $99
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 22 | $752 |
| GlaxoSmithKline, LLC. | 31 | $669 |
| AstraZeneca Pharmaceuticals LP | 28 | $658 |
| Novartis Pharmaceuticals Corporation | 17 | $519 |
| CSL Behring | 20 | $510 |
| Regeneron Healthcare Solutions, Inc. | 13 | $313 |
| Organon LLC | 6 | $277 |
| LEO Pharma Inc. | 10 | $208 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $194 |
| ABBVIE INC. | 8 | $146 |
Products named: DUPIXENT, NUCALA, TEZSPIRE, TRELEGY ELLIPTA, Haegarda, VTAMA, Andembry, ADBRY.
Industry payments across NY — which companies pay providers there.
